Company / Cash & Equivalents
Neurogene Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$103.8M
FY2025
5-year range
$76.9M / $143.1M
FY2021-FY2025
Trend
-24.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $143M to $104M over the past 6 years.
Based on SEC 10-K filings.
$104M in FY2025.
Declined from $143M to $104M over the past 6 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 24.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.24 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $103.8M | -24.0% |
| FY2024 | $136.6M | -4.5% |
| FY2019 | $143.1M | +86.0% |
| FY2018 | $76.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026